



醫院管理局  
HOSPITAL  
AUTHORITY

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

**Drug Advisory Committee January 2024 Meeting Outcome**

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
1	Abemaciclib	Verzenio	Malignant disease and immunosuppression	Approved	
2	Alpelisib	Piqray	Malignant disease and immunosuppression	Approved	
3	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Approved	
4	Bilastine	Labixten	Respiratory system	Rejected	Alternative(s) available in HADF with comparable benefits
5	Carglumic acid	Carbaglu	Nutrition and blood	Approved	
6	Dexamethasone	Ozurdex	Eye	Approved	
7	Dostarlimab	Jemperli	Malignant disease and immunosuppression	Approved	
8	Encorafenib	Braftovi	Malignant disease and immunosuppression	Approved	
9	Enfortumab vedotin	Padcev	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
10	Eptinezumab	Vyepti	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
11	Eribulin	Halaven	Malignant disease and immunosuppression	Approved	
12	Fosnetupitant/Palonosetron	Akynzeo	Central nervous system	Approved	
13	Ibrutinib	Imbruvica	Malignant disease and immunosuppression	Approved	
14	Insulin glargine	Toujeo	Endocrine system	Pending	Pending further information
15	Isatuximab	Sarclisa	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
16	Luspatercept	Reblozyl	Nutrition and blood	Approved	
17	Onasemnogene abeparvovec	Zolgensma	Musculoskeletal and joint disease	Approved	

	<b>Generic name</b>	<b>Brand name</b>	<b>Therapeutic Class</b>	<b>Meeting outcome</b>	<b>Primary reason for rejection<sup>1</sup></b>
18	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
19	Rurioctocog alfa pegol	Adynovate	Cardiovascular system	Rejected	Alternative(s) available in HADF with comparable benefits
20	Selinexor	Xpovio	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
21	Tepotinib	Tepmetko	Malignant disease and immunosuppression	Approved	
22	Tisagenlecleucel	Kymriah	Malignant disease and immunosuppression	Approved	

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.